289 related articles for article (PubMed ID: 22313330)
1. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
2. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Nov; 9(6):377-87. PubMed ID: 21888449
[TBL] [Abstract][Full Text] [Related]
3. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
Copher R; Cerulli A; Watkins A; Laura Monsalvo M
J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Curr Med Res Opin; 2011 Sep; 27(9):1763-8. PubMed ID: 21793646
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
8. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
Lupus; 2013 Mar; 22(3):268-78. PubMed ID: 23340996
[TBL] [Abstract][Full Text] [Related]
9. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
11. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
14. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population.
Furst DE; Fernandes AW; Iorga SR; Greth W; Bancroft T
J Rheumatol; 2012 Dec; 39(12):2303-9. PubMed ID: 23027885
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
16. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
17. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
18. [The oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension].
Cui N; Yang YH; Xie WM; Ma ZH; Luo L; Wang C
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):522-6. PubMed ID: 19954007
[TBL] [Abstract][Full Text] [Related]
19. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
20. Burden of illness in idiopathic pulmonary fibrosis.
Collard HR; Ward AJ; Lanes S; Cortney Hayflinger D; Rosenberg DM; Hunsche E
J Med Econ; 2012; 15(5):829-35. PubMed ID: 22455577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
